Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (POSEIDON)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03736447
Recruitment Status : Completed
First Posted : November 9, 2018
Last Update Posted : July 25, 2022
Information provided by (Responsible Party):
Aimmune Therapeutics, Inc.

Brief Summary:
The purpose of this study is to determine the efficacy and safety of AR101 in peanut-allergic children aged 1 to < 4 years.

Condition or disease Intervention/treatment Phase
Peanut Allergy Biological: AR101 powder Biological: Placebo powder Phase 3

Detailed Description:
To determine the efficacy and safety of AR101 in a characterized oral desensitization immunotherapy (CODIT™) regimen compared with placebo in peanut-allergic children aged 1 to < 4 years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 146 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: 2:1 randomization
Masking: Triple (Participant, Care Provider, Investigator)
Masking Description: Double-Blinded
Primary Purpose: Treatment
Official Title: Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (POSEIDON)
Actual Study Start Date : December 27, 2018
Actual Primary Completion Date : July 5, 2022
Actual Study Completion Date : July 5, 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: AR101 powder (Peanut allergen formulation)
Subjects will be randomized to active arm of ARC005 and will be administered IP (AR101) in escalating doses for approximately 6 months.
Biological: AR101 powder
AR101 powder provided in capsules and sachets (peanut allergen formulation)

Placebo Comparator: Placebo powder
Subjects will be randomized to placebo arm of ARC005 and will be administered escalating doses of IP (placebo) for approximately 6 months.
Biological: Placebo powder
Placebo powder provided in capsules and sachets

Primary Outcome Measures :
  1. Efficacy of AR101 [ Time Frame: 12 months ]
    The proportion of subjects treated with AR101 compared with placebo who tolerate an at least 600 mg single dose (for patients in the US) or 1000 mg single dose (for patients in Europe) of peanut protein with no more than mild allergy symptoms during the exit double-blind placebo-controlled food challenge (DBPCFC).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   1 Year to 3 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Aged 1 to < 4 years at randomization.
  • Written informed consent from the legal guardian/parent (or both parents where required by local authorities). Provide assent where required and as appropriate per local requirements.
  • Sensitivity to peanut, defined as one of the following:

No known history of peanut ingestion and has serum IgE to peanut ≥ 5 kUA/L within 12 months before randomization.

Documented history of physician-diagnosed IgE-mediated peanut allergy that includes the onset of characteristic* signs and symptoms of allergy within 2 hours of known oral exposure to peanut or peanut-containing food, and has a mean wheal diameter on skin prick test (SPT) to peanut of at least 3 mm greater than the negative control (diluent) or serum IgE to peanut ≥ 0.35 kUA/L, obtained within 12 months before randomization.

  • Development of age-appropriate dose-limiting allergy symptoms after consuming single doses of peanut protein > 3 mg to ≤ 300 mg in a screening DBPCFC.
  • A palatable vehicle food to which the subject is not allergic must be available for administering study product.

Exclusion Criteria:

  • History of severe or life-threatening anaphylaxis anytime before the screening DBPCFC.
  • History of hemodynamically significant cardiovascular or renovascular disease, including uncontrolled or inadequately controlled hypertension.
  • History of biopsy-confirmed diagnosis of EoE; other eosinophilic GI disease; chronic, recurrent, or severe gastroesophageal reflux disease (GERD); or symptoms of dysphagia (eg, difficulty swallowing, food "getting stuck").
  • Recurrent GI symptoms considered clinically significant in the opinion of the investigator.
  • History of a mast cell disorder including mastocytosis, urticaria pigmentosa, chronic idiopathic or chronic physical urticaria beyond simple dermatographism (eg, cold urticaria, cholinergic urticaria), and hereditary or idiopathic angioedema.
  • Moderate or severe persistent asthma (criteria steps 3-6; National Heart, Lung, and Blood Institute [NHLBI], 2007).
  • Mild asthma (criteria steps 1-2; NHLBI, 2007) that is uncontrolled or difficult to control based on NHLBI 2007 criteria.
  • History of high-dose corticosteroid use (eg, 1-2 mg/kg prednisone or equivalent for > 3 days) by any route of administration as defined by any of the following:

    • Steroid administered daily for > 1 month within 1 year before screening
    • One steroid course within 6 months before screening
    • More than 2 steroid courses ≥ 1 week in duration within 1 year before screening
  • History of food protein-induced enterocolitis syndrome (FPIES) within 12 months before screening.
  • Recurrent urticaria.
  • History of failure to thrive or any other form of abnormal growth, or developmental or speech delay that precludes age-appropriate communication.
  • History of chronic disease (except mild intermittent asthma, mild persistent asthma that is controlled, atopic dermatitis, or allergic rhinitis) that is or is at significant risk of becoming unstable or requiring a change in a chronic therapeutic regimen.
  • Unable to discontinue antihistamines and other medications that could interfere with the assessment of an allergic reaction for 5 half-lives of the medication before the screening SPT, first day of dose escalation, and DBPCFCs.
  • Use or anticipated use of a prohibited medication (eg, beta blockers [oral], angiotensin converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, or tricyclic antidepressants), monoclonal antibody, or any other immunomodulatory therapy (including immunosuppressive medications).
  • Treatment with any form of immunotherapy for any food allergy anytime before screening.
  • Participation in another clinical trial within 30 days or 5 half-lives of the investigational product, whichever is longer, before screening.
  • Allergy to oat or rice.
  • Hypersensitivity to epinephrine or any of the excipients in the epinephrine auto-injector.
  • Parent/caregiver unable or unwilling to use epinephrine auto-injectors.
  • Unable to follow the protocol requirements.
  • Any other condition (concurrent disease, infection, comorbidity, or psychiatric or psychological disorders) or reason that may interfere with the ability to participate in the study, cause undue risk, or complicate the interpretation of data, in the opinion of the investigator or medical monitor.
  • Resides at the same place as another subject in any AR101 interventional trial.
  • Lives in the same household and/or is a family member of a sponsor employee or site staff involved in conducting this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03736447

Show Show 23 study locations
Sponsors and Collaborators
Aimmune Therapeutics, Inc.
Layout table for investigator information
Study Director: Freddy Byrth Aimmune Therapeutics
Additional Information:
Layout table for additonal information
Responsible Party: Aimmune Therapeutics, Inc. Identifier: NCT03736447    
Other Study ID Numbers: ARC005
First Posted: November 9, 2018    Key Record Dates
Last Update Posted: July 25, 2022
Last Verified: July 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Aimmune Therapeutics, Inc.:
CODIT™ (characterized oral desensitization immunotherapy™)
Peanut-Allergic Children
CPNA (Characterized Peanut Allergen)
Peanut Allergy
Characterized Peanut Allergen
Oral Immunotherapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Peanut Hypersensitivity
Immune System Diseases
Nut and Peanut Hypersensitivity
Food Hypersensitivity
Hypersensitivity, Immediate